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Abstract 
Background: Difficulties in diagnosis, treatment, and chronic management of 
Crohn's Disease (CD) may explain the variation in diagnostic evaluation and 
treatment therapies seen among providers. Our systematic literature review shows 
that published guidelines do not fully address management of pediatric CD. 
Therefore, using the Quality hnprovement Model, we can systematically gather 
data from experts on the best way to change current CD management. 
Objective: To determine if conjoint analysis can summarize current beliefs among 
pediatric gastroenterologists on the relative importance of implementing 
evidence-based changes to improve outcomes of children with CD. 
Methods: We administered an online survey, Physicians Beliefs on Crohn's 
Management, to a convenience sample of 12 members of the Pediatric 
Inflammatory Bowel Disease (PillD) Network. We asked participants to rank 16 
different clinic scenarios based on which ones were most likely to improve patient 
outcomes and analyzed the ranking through conjoint analysis. 
Results: One physician completed the survey for a response rate of 8.3%. Results 
suggest that decreasing steroid use is most likely to improve outcomes while 
planned care and optimizing nutrition are least likely to improve outcomes. We 
found the largest effect of interaction to be between standardizing diagnostic 
evaluation and planned care. 
Conclusion: Conjoint analysis has the potential to summarize current beliefs 
among pediatric gastroenterologists regarding CD management, but before it can 
be used reliably, it needs to be tested on a larger sample. 
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Introduction 
Pediatric inflammatory bowel disease (IBD) is a chronic, destructive 
inflammatory disease of tbe gastrointestinal tract. 1 Children with IBD can be 
further described as having either Crohn's disease (CD) or ulcerative colitis (UC). 
CD is characterized by ulcerations and scarring of the terminal ileum and 
proximal colon, but can affect any part of the gastrointestinal tract. 2 Patients 
typically complain of abdominal pain, diarrhea and weight loss, but can also 
present with blood or mucus in stools, fatigue, growth failure, delayed puberty, or 
extraintestinal symptoms (erythema nodosum, aphthous ulcers, arthritis, ocular 
disease, etc.). The estimated incidence of pediatric CD in the United States is 4.56 
cases per I 00,000 children for all racial and etbnic groups.1 Approximately 80% 
of cases are diagnosed after age 10, with an average age of diagnosis of 13.5 years. 
Only 12% of cases are in children with a positive family history of CD. 
Managing children with CD can be difficult. Although characteristics of 
CD and UC are very different in adults, they are not as distinct in children? For 
example, adults with CD typically present witb diarrhea while those with UC 
present with rectal bleeding. However, children with either CD or UC present 
with abdominal pain. This suggests that clinical symptoms may not be helpful in 
diagnosing children with CD. Secondly, our understanding of the etiology of CD 
is limited. Development of this disease depends only partially on genetic factors.4 
Potential nongenetic factors include smoking, use of nonsteroidal anti-
inflammatory drugs, or the presence of certain micro flora in tbe gut. We cannot 
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explain how these environmental factors lead to the development of CD, making 
it difficult to find effective treatments. Finally, CD is a chronic disease, affecting 
individuals throughout their childhood and adulthood. To manage such 
individuals, it is important to provide self-management support, coordinate proper 
interdisciplinary care, and follow evidence based clinical practice guidelines. 5 
Together, difficulties in diagnosis, treatment, and chronic management 
may explain the variation that Colletti eta!. found in diagnostic evaluation and 
treatment therapies for pediatric CD patients at 30 different IBD clinics.6 For 
example, only 75% of pediatric gastroenterologists completed stool cultures to 
rule out an infectious process, 6 despite the fact that this is recommended for all 
patients3. Similarly, 63% used mesalamine for treatment, 6 but this drug is 
considered first line treatment for all patients with mild CD.7 Although variation 
in care often exists because we do not know the best way to care for a disease, 
variation may also exist because we know the best way to manage the disease, but 
not all practices have implemented it. For this second reason, consensus based and 
evidence based guidelines can improve quality of care by assisting all physicians 
in providing the best care to patients. 8 
To address this variation in care, we completed a two part study. We first 
conducted a systematic review on current recommendations for diagnosing, 
treating, and managing pediatric CD. We then surveyed pediatric 
gastroenterologists and, using conjoint analysis, summarized their current beliefs 
on the best way to change current CD management to improve patient outcomes. 
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Quality Improvement 
Definition of Quality Improvement 
Quality Improvement (QI) is a set of methods designed to improve the 
performance of systems. 9 A system is "A network of interdependent components 
that work together to accomplish a shared aim".1° For example, the network of 
activities performed in a CD outpatient clinic is a system that creates a particular 
set of outcomes. To meaningfully improve these outcomes, we cannot make 
changes such as hiring more nurses for each clinic or asking doctors to work 
longer hours because these are merely ways of adding resources. Instead, QI 
involves changing the way components of a system work together. 
In order to conduct QI, we need to understand the following theoretical 
and methodological principles of QI.11 The four principles are: I) appreciation of 
the system; 2) learning from variation; 3) building knowledge through testing; and 
4) human reaction. 
Appreciation of the System 
This first principle means that to improve outcomes, you must first 
understand that they are the result of a system or a set of care processes.11 
Therefore, to improve the result you need to identify the system. One way to 
describe a system that is applicable to CD patients is to use Wagner's chronic 
illness care model.5 In this model, community resources and policies interact with 
the health care system, which is defined as family and self management, delivery 
system design, decision support, and clinical information systems. As the name 
implies, family and self management is when CD patients and their families 
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manage their chronic illness. Delivery system design describes the roles and 
activities of staff within CD clinics. Decision support refers to processes that 
support the use of evidence based care by the provider. Finally, a clinical 
information system aids providers in monitoring the overall care of each patient as 
well as all the patients in the practice. 
Learningfrom Variation 
If all systems are not standardized then we will observe 2 types of 
variation in the results. 11' 12 The first type of variation is variation due to chance, 
which typically falls within± 3 standard deviations of the mean. The second type 
of variation is due to differences in systems and is defined as > 3 standard 
deviations from the mean. For example, not all outpatient CD clinics have the 
exact same infrastructure. Depending on location or funding, the clinics may have 
different services or referral resources. This variation between systems may lead 
to significant variation in outcomes for CD patients. By studying the second type 
of variation, we can learn which changes to a system may lead to improvement in 
. 12 pat1ent outcomes. 
Building Knowledge through Testing 
QI methods represent a means of applying the scientific method to learn 
rapidly in a complex organizational system. An example of such a tool is the 
model for improvement created by Langley et al.11 The two component model is 
designed to help individuals apply the scientific method to the improvement of 
systems. The first component is the planning component, which is comprised of 
three main questions: 1) What are we trying to accomplish? 2) How will we know 
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that a change is an improvement? and 3) What changes can we make that will 
result in improvement? The second component, the action component, was first 
developed by WE Deming for quality management and is comprised of 
continuous Plan-Do-Study-Act cycles. During the Plan phase, we identify the 
problem and the changes we would like to make. In the Do phase, we implement 
a change, often on a small scale, and then during the Study phase we evaluate the 
effects of the change in comparison to our aim. Finally, during the Act phase, we 
formalize the change and consider implementing it on a larger scale. QI should be 
a continuous process because our enviromnent is constantly changing. Therefore, 
after the Act phase, we return to the Plan phase to decide what other changes 
should be made. 
Human Reaction 
The last principle of QI is anticipating how individuals will react to the 
changes.11 For example, providers may react positively to a new standardized 
diagnostic protocol because they feel that it simplifies diagnostic evaluation and 
leads to proper diagnoses of all their patients. On the other hand, they may react 
negatively because the new protocol may influence long established habits. 
Applying Quality Improvement Models to Pediatric CD Management 
Significance of QI 
In 2001, the Institute ofMedicine (IOM) concluded that a large chasm 
exists between the health care we have and the health care we could have.13 This 
lack of quality health care is from underuse, overuse, and misuse of health care 
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services. 14 The root of these three problems are the increase in prevalence of 
chronic diseases, the growing complexity of science and technology, and our 
poorly organized health care delivery system.15 To address the health care chasm, 
the IOM created 10 "rules" that would redesign our current health care system.13 
Rule number 5 encouraged the use of evidence based care because systematic 
reviews and clinical guidelines along with reminder systems can improve patient 
care. To provide consistent, high-quality care to patients with CD, we can use QI 
methods to identifY and develop clinical guidelines. 
Idealized Design 
To identify the best way to manage pediatric CD, we need to first develop 
a theory or hypothesis for which changes in management of pediatric CD will 
improve outcomes. As the systematic literature review below will show, we have 
very few published guidelines on CD management that we can follow. Since we 
cannot use the literature to define our recommended changes in management, we 
must systematically gather data from experts in the field. The protocol that we 
will follow is based on the Idealized Design Process described by Ronald Moen in 
"A Guide for Idealized Design".16 This explicit process for design improvement is 
based on prior strategies used in industry. Moen describes 6 phases, starting from 
Phase 0 and ending with Phase 5. During Phase 0, which is the focus ofthis study, 
we generate new ideas for restructuring the current system in such a way that we 
improve the quality of care patients receive. During Phases I through 4, the new 
ideas are tested and, finally, during Phase 5, the ideas are disseminated. 
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The first Idealized Design project was led by the Institute for Healthcare 
Improvement (IHI) in January 1999.16 The IHI wanted to redesign the health care 
system by starting with the clinical office practice. 17 The Idealized Design of 
Clinical Office Practice (IDCOP) initiative involved 42 practices that tried to 
improve patient satisfaction, access to care, and the quality of outpatient care. One 
practice increased their overall percentage of high patient satisfaction from 72% 
to 95%.18 They increased access to care by decreasing their waiting time for an 
appointment from 59 days to 1 day. Finally, they improved clinical outcomes by 
increasing the percent of diabetic patients who monitor their blood glucose at 
home from 54.3% to 72.4%. 
Change Concepts 
Using the steps in Phase 0 of the Idealized Design Process outlined in 
Appendix A, experts in quality improvement and pediatric gastroenterology 
identified 5 changes to CD management that they hypothesize will improve 
outcomes.16 As the first step, our sponsors, the North American Society for 
Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the 
American Board of Pediatrics, selected pediatric CD as the topic of interest and 
provided funding. Next, 2 experts in quality improvement and 3 experts in 
pediatric gastroenterology formed a team to address this topic. Using questions 
from the planning component of the model for improvement, the team developed 
a charter with the goal of improving outcomes for children with CD. For the 5'h 
step, the 5 experts reviewed both research based evidence and anecdotal evidence 
on managing Crohn's disease. They used the Chronic Illness Care model by 
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Wagner as a framework to organize the evidence.5• 19 Next, the team selected a 
large hospital in the northeastern US and observed how patients were managed at 
the CD clinic. They then held a meeting to brainstorm ideas for improvement 
based on their observations. Next (step 9), they held a meeting of 20 pediatric 
gastroenterologists who are recognized experts in CD to narrow down the ideas. 
At the meeting, experts identified 5 changes to CD management and 5 
outcomes to measure improvement in care. The 5 change concepts were the 
following: 1) standardize diagnostic evaluation; 2) optimize nutritional 
assessment and management; 3) planned care; 4) promote patient and family self 
management; and 5) decrease use and duration of steroids. For details on the 
definitions of each change concept, please refer to Appendix B. The outcomes 
were reducing overall disease activity, increasing quality oflife, achieving normal 
growth, decreasing complications ofiDD, and decreasing medication side effects. 
Quality oflife would be measured using IMP ACT 35, which is a validated 35 
question survey designed for children and adolescents that determines the effect 
ofiDD on health.20 To determine what pediatric gastroenterologists hypothesize is 
the effectiveness of each of the 5 change concepts for improving patient outcomes, 
we will conduct a conjoint analysis, as recommended in Phase 0 (Appendix A). 
Conjoint Analysis 
Conjoint analysis has been used traditionally in marketing research to 
determine consumer preferences by assessing the relative importance of groups of 
attributes. 21 This allows us to calculate which attribute is the most important and 
which less important attributes consumers are willing to give up for their most 
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important attribute. 22 We can then predict which trade-offs consumers will make 
when purchasing a product. This indirect method is more effective than directly 
asking the consumer because, similar to real life, it forces the consumer to make 
trade-offs.23 
In clinical trials, interventions are done one at a time. This allows us to 
compare one single intervention to placebo or standard care and determine which 
is better. However, in clinical practice, many interventions are made at once, 
making it difficult to identify which change had the largest effect. Sometimes two 
interventions interact synergistically such that the effect of both changes is greater 
than the effect of each on its own. Similar to real clinical settings, a conjoint 
analysis allows us to hypothesize which intervention has the largest effect and 
which two changes work synergistically when many changes are made at once. 
Three types of conjoint analysis exist and depending on the type of 
research, one is usually more appropriate than the others.Z4 Choice-Based 
Conjoint (CBC) uses interview questions that mimic the process for purchasing 
competing products. CBC is appropriate for predicting product choices and for 
measuring interactions between attributes that have more than 3 levels. For 
example, 5 different sedans may be described by 4 attributes: price, gas mileage, 
safety rating and color. Each attribute can then have different levels. An attribute 
with more than 3 levels could be car color because the sedan may come in blue, 
green, red and gray. Rather than rank the 5 cars, respondents are asked to choose 
the one they would purchase. For this study, we were more interested in the 
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importance of attributes rather than predicting product choices. Therefore we 
decided that CBC was not appropriate for this study. 
The second type of conjoint analysis is Adaptive Conjoint Analysis (ACA), 
which asks respondents to first rank all of the attributes and then compare pairs of 
products with different levels for each attribute.24 ACA is computer administered 
because interview questions are adapted to the respondents' previous answers. 
This allows respondents to evaluate 8-15 attributes without being overloaded by 
seeing all attributes at once. ACA also allows the researcher to have a smaller 
sample size because the estimates of the respondent's preferences are more 
accurate. Since this study only has 5 change concepts or attributes, we felt that the 
complexity of ACA was unnecessary. 
Traditional Full-Profile Conjoint Analysis (CV A) is the third type of 
conjoint analysis and is the most appropriate type of analysis for this study. 24 
Respondents are asked to rank products with different levels for each attribute. 
CV A can only be used to evaluate up to 6 attributes because respondents must see 
all the products and their attributes at once. If respondents are asked to evaluate 
more than 6 attributes, they cannot process them effectively. Similar to CBC, 
CV A can measure interactions between attributes, but the attributes must have 
less than 3 levels. For this study, we chose CV A because we have 5 attributes and 
each attribute has 2 levels. There are only two levels because each change concept 
is either implemented or is not implemented. 
At the end of the conjoint analysis, we will determine ifCVA is an 
appropriate method for identifying which change or changes pediatric 
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gastroenterologists hypothesize will most improve outcomes for CD patients. 
With this expert generated hypothesis, NASPGHAN and the American Board of 
Pediatrics will enter the Plan phase of the PDSA cycle, where they will develop 
an intervention to test the hypothesis. After several PDSA cycles, they can 
provide evidence either supporting or refuting the hypothesis from our conjoint 
analysis. 
Systematic Review of Clinical Recommendations for Crohn's Management 
To identify standard practices for CD management, we conducted a 
systematic review of the literature regarding current guidelines on the diagnosis, 
treatment and management of pediatric CD. Only some of the articles provided 
guidelines on our 5 concept changes (Appendix B). We critically appraised the 
selected articles using the 25 item questionnaire developed by Shaneyfelt, Mayo-
Smith, and Rothwangl.25 
Article Selection 
We searched Pubmed, Ovid and Clearinghouse Guidelines databases for 
relevant articles using different combinations of the following search string: 
pediatric, IBD or Crohn's disease, and recommendations or guidelines. Articles 
were limited to those published in English before March 2006 and included a list 
of guidelines or recommendations for pediatric Crohn's disease. As Figure 1 
shows, our online search resulted in 73 articles, 9 of which had potentially 
relevant titles. Of the 9 abstracts, only 7 were relevant to this topic. This author 
(SM) reviewed the 7 articles and identified 4 of them that met inclusion criteria. 
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The hand search of bibliographies from relevant articles and consultation with 
experts in the field of pediatric gastroenterology led to acceptance of one other 
article for the systematic review. 
Literature Appraisal Methods 
The 25 item questionnaire for guidelines uses a yes or no format to 
measure how well published guidelines follow standards on guideline format and 
development (1 0 questions), on identification and summary of evidence (1 0 
questions), and on formulation of recommendations (5 questions).25 Each question 
is worth 1 point, such that the ideal guidelines would have all 25 items and would 
receive 25 points. Shaneyfelt, Mayo-Smith, and Rothwangl reviewed 279 
guidelines which had a mean score of 10.77 with a standard deviation of3.7. 
Using these results, we defmed a set of guidelines as good if they were more than 
1 standard deviation above the mean, fair if they were ± 1 standard deviation from 
the mean, and poor if they were more than 1 standard deviation below the mean. 
Therefore, poor guidelines would have a score less than 8, fair guidelines would 
have a score between 8 and 14 and good guidelines would have a score above 14 
(see Table 1 ). 
Standardized Diagnostic Evaluation 
Of the five articles that met inclusion criteria, only one suggested 
guidelines on how to diagnose children with Crohn's disease3 Published by the 
IBD working group of the European Society for Paediatric Gastroenterology, 
Hepatology, and Nutrition (ESPGHAN), this article describes a protocol 
consisting of laboratory tests, endoscopies, biopsies, and imaging for diagnosing 
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Crohn' s disease. The guidelines received a score of 7 for following standards on 
guideline format and development, a score of 1 for identification and summary of 
evidence, and a score of2 for formulation of recommendations (see Table 2). 
Unlike the other articles, these guidelines did not discuss health 
outcomes. 3 This may be because they were focused on appropriate diagnosis for 
furthering epidemiological data on this disease. Indirectly, the authors are 
suggesting that by gathering more data on this disease, we may be able to 
understand it better and hence improve treatment and outcomes. However, the 
authors did not suggest that, by standardizing the diagnostic evaluation, patients 
will be appropriately diagnosed, which would improve health outcomes. 
ESPGHAN' s recommendations for diagnosis did not describe their guideline 
development or their procedure for identifying evidence, which explains their 
poor score for the second section of the questionnaire. For the last section, the 
recommendations were flexible and specific to the goals of the guidelines. 
However ESPGHAN did not formally grade the recommendations, nor did they 
discuss patient preference or the role of value judgments. 
Based on the Porto criteria3 and the limited articles on diagnosing IBD, 
there seems to be some controversy on how to differentiate children with CD and 
UC. Since it is unclear in the literature on how to best diagnose CD in children, 
pediatric gastroenterologists may disagree on the impact of a standardized 
diagnostic evaluation. 
Optimize Nutritional Assessment and Management 
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Only one article addressed nutritional assessment and management. 26 The 
American Society for Parenteral and Enteral Nutrition (ASPEN) recommended 
nutrition screening for all children with IBD and provided guidelines for usage of 
enteral or parenteral nutrition. For guideline format and development the ASPEN 
guidelines received a score of 9, for identification and summary of evidence they 
received a score of3, and for formulation of recommendations they received a 
score of 3 (see Table 2). 
For the first section of the questionnaire, the ASPEN guidelines discussed 
everything except an expiration date.27 Authors did report that ASPEN would 
continue to review the guidelines and update them on a certain schedule, but then 
they did not publish this schedule. For the second section, the guidelines cited and 
graded evidence and discussed harms and benefits, but did not define their 
methods for data extraction and consolidation. Finally, for the third section, 
ASPEN did not describe the role of value judgments and patient preference. 
The guidelines on nutritional assessment and management, although 
sparse, seem very clear. Most pediatric gastroenterologists should agree that all 
physicians should optimize nutrition for pediatric CD patients. However, the 
feasibility of optimizing nutrition may be limited and may decrease its impact for 
. . 28 1mprovmg outcomes. 
Planned Care 
Planned care is when an interdisciplinary team meets regularly to review a 
patient's chart and any other patient information and plans what to do next. 
Typically, the review focuses on disease activity, nutritional status, functional 
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activity, and the medication list. Then, the team identifies problems in one or 
more of these areas and creates a plan for patient interaction. No published 
guidelines addressed the issue of planned care in the management of CD. There 
are no recommendations on who should be involved in the meetings, what areas 
of disease management should be discussed, and even if planned care should be 
implemented in all practices. Since there are no recommendations, it is difficult to 
predict what most pediatric gastroenterologists believe is the impact of planned 
care. 
Promote Patient and Family Self Management 
We found no guidelines that encouraged or discouraged the promotion of 
patient and family self management. Similar to planned care, it is difficult to 
predict what pediatric gastroenterologists believe is the impact of self 
management. 
Decrease Use and Duration of Steroids 
Only one article reviewed the evidence for various medical therapies, 
described side effects, and suggested usage and dosage for each medical therapy.7 
These recommendations received a score of 7 for following standards on 
guideline format and development, a score of 2 for identification and summary of 
evidence, and a score of3 for formulation of recommendations (see Table 2). 
For the first section of the questionnaire, Escher et aL did not mention 
their intended audience or users, their external review process, or an expiration 
date for their guidelines. 7 Similar to the diagnostic recommendations, the 
treatment recommendations did not clearly explain their guideline development or 
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their procedure for identifYing evidence. Escher et a!. did summarize the potential 
side effects of each treatment in detail. They did not, however, describe how they 
identified the evidence, what time period it came from, how it was extracted and 
combined, or if the evidence was of high quality. While we know the benefits and 
harms ofthe treatments, we are not told how much they cost. Although the 
authors of this article gave recommendations for treatment, they may describe this 
article as a review rather than a set of guidelines. If this is true, then they may not 
have felt it was necessary to grade their recommendations or explain how they 
combined their evidence. This does not explain why they did not describe their 
methods for data extraction. Finally, Escher et a!. described how they created their 
recommendations, but they did not mention patient preference or the role of value 
judgments. 
Besides this one article on recommendations for CD treatment/ there are 
many reviews in the literature discussing treatment options.4' 28 There seems to be 
some consensus on which class of drugs is best for CD treatment and the 
importance oflimiting steroids. Therefore, pediatric gastroenterologists are likely 
to agree on the impact of steroid reduction on patient outcomes. 
Other Aspects of CD Management 
The remaining two articles did not address any of our 5 change concepts, 
but they did address other important management issues. One article addressed 
whether routine childhood vaccinations are safe for children with Crohn's 
disease.29 For guideline format and development, the guidelines received a score 
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of 7, for identification and summary of evidence they received a score of 2, and 
for formulation of recommendations they received a score of3 (see Table 2). 
Similar to the treatment recommendations by Escher et al., the vaccination 
guidelines did not mention their intended audience or users, their external review 
process, or an expiration date for their guidelines.Z9 Authors cited their evidence 
and discussed the harms and benefits of vaccination in depth. However, the 
authors did not explain in detail how they identified their evidence or how they 
developed their guidelines. Lastly, the guidelines were flexible and specific to 
guideline goals, but did not discuss patient preference or grade the immunization 
guidelines. L 
The other article not addressing any change concepts described strategies 
for preventing and treating osteoporosis in mD?0 The guidelines received a score 
of 8 for following standards on guideline format and development, a score of 6 for 
identification and summary of evidence, and a score of 5 for formulation of 
recommendations (see Table 2). 
For the first section of the questionnaire, Scott et al. explained their 
external review process but did not give an expiration date for their guidelines. 30 
For the second part, they described how they identified, extracted and graded their 
evidence and discussed the harms and benefits of treatment. For the last part, 
these guidelines met all the criteria. 
Overall Findings of Systematic Review 
The diagnostic recommendations byESPGHAN met 10 of the guideline 
standards. The medical treatment recommendations and the immunization 
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guidelines each met 12 of the standards. The ASPEN guidelines met 15 of the 
standards and the osteoporosis guidelines met 19 of the standards. Based on these 
results, the ESPGHAN, medical treatment, and immunization guidelines were fair 
while the osteoporosis and ASPEN guidelines were good (see Table 2). 
For guidelines to be useful, they need to be up to date. On the other hand, 
determining how long they will be accurate can be difficult because we cannot 
often predict when medicine will change. This may explain why none of the 
articles published an expiration date for their recommendations. Another 
explanation may be that the group that publishes the guidelines must constantly 
review the literature and make changes to guidelines on a regular basis. Except for 
ASPEN, none of the other groups were willing to make such a commitment. 
None of the 5 articles attempted to quantify benefits and harms or health 
care costs. These results are similar to findings by Shaneyfelt, Mayo-Smith, and 
Rothwangl, who reported that only 14.3% of279 guidelines quantified health care 
costs.Z5 We believe practice guidelines can play a role in decreasing health care 
costs because they have the potential to decrease mistakes and decrease misuse, 
overuse, and underuse of medical care. However, very few guideline developers 
attempt to prove or disprove this belief. This may be because most guideline 
developers are physicians who have minimal expertise in running cost benefit 
analyses. Costs may be overlooked because physicians are more focused on 
providing patients with proper medical care. Finally, authors may not quantify 
costs because they believe they are not responsible for lowering health care costs. 
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All five articles describe flexible guidelines that allow the health care 
provider to use his or her judgment before finalizing a plan of action. However, 
only one article suggests that the provider should consider their patient's 
judgment when deciding appropriate medical care. Guidelines developers may not 
discuss patient preferences because they believe that by giving health care 
providers flexibility, providers can then take into account patient preferences. On 
the other hand, guideline developers may believe that patient preferences should 
not influence care decisions. 
Significance ofthis Study 
Currently, published guidelines do not fully address management of 
pediatric CD. The systematic review shows that guidelines for the diagnosis and 
treatment of CD are ofliruited quality, and the good guidelines that do exist only 
address osteoporosis and nutrition. We do not have any recommendations 
discussing patient education or interdisciplinary care, which play a large role in 
managing chronic diseases. 5 Since current literature on CD management is limited, 
we would like to begin an improvement collaborative that develops information 
about what combination of the 5 change concepts improves outcomes for CD 
patients the most. This will be a 2'5•1 factorial, time series study where each 
practices adopts one or more of the 5 change concepts and then measures each 
patient outcome for improvement. Before we conduct the study, however, we 
would like to formally determine which change concept( s) pediatric 
gastroenterologists hypothesize will improve outcomes the most. 
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To determine if conjoint analysis can summarize pediatric 
gastroenterologists' beliefs on the relative importance and feasibility of 
implementing evidence-based changes to improve outcomes of children with CD, 
we administered a survey and conducted a conjoint analysis according to the 
methods of QI. Based on the literature review, we would expect there to be 
variation in providers' beliefs on diagnosing children with CD, but not for 
optimizing nutrition or decreasing steroid use. For planned care and patient and 
family self management, it is difficult to predict provider beliefs. 
Study Methods 
Study Population 
The Pediatric Inflammatory Bowel Disease (PIBD) Network for Research 
and hnprovement is a collaborative network that allows all physicians in North 
America who are board certified in pediatrics and gastroenterology to work 
together to improve the health care of children with IBD.31 This network provides 
a secure online system that stores and analyzes data. As of March 2006, there 
were a total of72 pediatric gastroenterologists who had entered patient data into 
the PIBD database. There were 58 males and 14 females ranging in age from 
approximately 30 years to 70 years old. Race and ethnicity of providers was not 
reported in the PIBD database. Physicians that played a role in designing and 
testing the survey were not included in our study. 
Rather than contacting all 72 members to volunteer for our study, we 
gathered a convenience sample of 12 physicians by asking the leaders of one large 
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academic practice and one small private practice if they would be willing to join 
our study. Although a random sample of volunteers would have been ideal, we 
felt we could increase our response rate by asking groups that were more likely to 
respond. 
Survey Development 
To determine which of the 5 change concepts pediatric gastroenterologists 
view as most important for improving outcomes of children with CD, we used 
CV A to develop a survey for PIBD network members. The first question in the 
Physicians Beliefs on Crohu's Management Survey asked physicians to rank 
clinic scenarios from 1 to 16, based on most likely to improve outcomes for 
children with CD. Scenarios that were ranked closer to 1 had a higher ranking and 
were more likely to improve outcomes, while scenarios that were ranked closer to 
16 had a lower ranking and were less likely to improve outcomes. Each clinic 
scenario either did or did not implement each of the 5 change concepts. For 
example, in one scenario the physician may evaluate a patient using a 
standardized diagnostic tool and may promote patient and family self 
management but may not implement the other three change concepts. Table 3 
summarizes the descriptors for each change concept used in the clinic scenarios. 
The second question in the survey asked physicians to rate the feasibility of each 
scenario with 1 being the most feasible and 5 being the least. 
There are 5 change concepts and each change concept has two levels 
because either the change is implemented or it is not implemented. Therefore, 
there are 2'5 or 32 different clinic scenarios. Based on our moderate knowledge on 
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managing CD, investigators decided to do a screening study to evaluate the 
impact of the changes and how they interact. 32 They determined that the survey 
needed to incorporate only 2'5•1 or 16 different clinic scenarios to give a 
preliminary sense of which combination of change concepts is most important. 
The non-shaded columns of Table 4 summarize the 16 clinic scenarios in matrix 
form and Appendix C shows the 16 scenarios in paragraph form. Therefore, to 
interpret scenario A in row I of Table 4, please refer to "Scenario A" in Appendix 
C. In the survey, the 16 scenarios were presented in a random order, and within 
each scenario the change concepts were also presented in random order. 
Before administering the survey, we piloted the survey twice. The first 
time, we provided 17 physicians and nurse practitioners with 16 scenarios in 
matrix form and in paragraph form. The matrix form quickly summarizes all of 
the scenarios in one table, but it may not be clear what it means to implement a 
change concept. Therefore, we developed a paragraph form for each scenario to 
describe only the changes that were to be implemented. We provided participants 
with both forms of the scenarios to ensure that each participant understood the 
scenarios. Pilot participants were then asked to rank the scenarios according to 
most likely to improve outcomes and to rate the feasibility of each scenario. 
In general, people reported that they were able to understand and rank the 
scenarios. Some of the participants reported that the survey only took 15 minutes 
because they looked at the matrix and based on the number of changes 
implemented, they ranked the scenarios. Other participants reported that they 
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preferred the paragraphs, but then to rank the scenarios they would extract how 
many changes were implemented in each scenario. 
The results showed that the survey had good face validity, because the 
scenarios we expected to improve outcomes were given a ranking between 1 and 
5 rather than 11 and 16. Figure 2 shows a dot diagram of the effect size of each 
change concept and the effect size of the interaction for each pair of change 
concepts. According to the dot diagram, decreasing steroid use (RX) is the change 
concept with the largest effect size because it is the furthest away from zero. 
When looking at the effect size of each pair, all of the pairs are around zero, 
suggesting no interaction between change concepts. In other words, no 2 change 
concepts seemed to work synergistically. The response plot in Figure 3 shows this 
lack of interaction graphically because the two lines are ahnost parallel. When 
decreasing use and duration of steroids is added to a scenario, the average ranking 
of the scenario is 6 points higher. Then, if patient and family self management is 
added to the scenario, the average ranking is about 3 points higher, independent of 
the presence of steroid use. 
Although we had no hypothesis for which two change concepts would 
have an interaction, we expected to find at least one interaction. We believe we 
saw no interaction because by ranking scenarios based on number of changes 
implemented, participants are not focusing on the scenario as a whole. They are 
not thinking that 2 specific changes, such as self management and reducing 
steroids, are more effective at improving outcomes than standard diagnostic 
evaluation, planned care, and optimal nutrition management. 
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To address the lack of interaction, we piloted the survey a second time on 
2 different providers (1 physician and 1 nurse practitioner). We provided this 
group with the 16 scenarios in paragraph form only. This time, the scenarios 
described both change concepts that were implemented and not implemented. We 
felt that by only providing the paragraph form and by describing both the 
implemented and not implemented change concepts, providers would have a 
harder time determining how many changes were implemented. Providers would 
be forced to look at the scenarios as a gestalt and give a ranking rather than 
systematically comparing the changes in each scenario. To discourage participants 
from taking the paragraph form of the scenarios and creating their own matrix, we 
asked them to spend no more than 30 minutes on the survey. 
The conjoint analysis showed that the survey had good face validity and, 
as expected, showed an interaction between 2 change concepts. Figure 4 shows a 
dot diagram of the results from the 2 providers. Similar to the first pilot study, the 
change concept with the largest effect size is reducing steroid use (RX) because it 
is the furthest away from zero. The largest interaction is between decreasing 
steroid use and self management because this effect size is furthest away from 
zero. This interaction can be seen visually by the intersecting lines in Figure 5. 
The response plot shows that the effect of decreasing steroid use is dependent on 
patient and self management and vice versa. Therefore, adding decreasing steroid 
use to a scenario increases ranking by 6.5 points if self management is absent but 
only by 1.5 points if self management is present. Similarly, adding self 
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management to a scenario increases ranking by 6.25 points if decreasing steroid 
use is absent but only by 1.25 if decreasing steroid use is present. 
Although both participants in the second pilot study recommended that the 
scenarios be shortened or provided in bullet format, we believed that the long 
scenarios accurately measured which change concepts were most important and 
had the ability to detect an interaction between 2 change concepts. Therefore, the 
survey format for this study is the same as the survey in our second pilot study. 
The University of North Carolina at Chapel Hill Institutional Review Board 
approved this final version of our survey. 
Data Collection 
Participants were emailed a cover letter which explained the purpose of 
this study, a copy of the questionnaire, and the definitions of the change concepts 
(Appendix B). If participants chose to enter the study then they consented to the 
study and filled out the survey anonymously at www.zoomerang.com. At the end 
of one week, each potential participant received an email reminding them to 
complete the Physicians Beliefs on Crohn' s Management Survey if they have not 
already done so and thanking those that had already responded. At the end of 3 
weeks, participants completed the study and were no longer contacted. 
Participants did not receive any incentive to complete the survey. Data was 
collected by www.zoomerang.com and then exported to Microsoft Excel. 
From the first two questions, we gathered data on the rank order and 
feasibility of the scenarios. The next two questions collected data on participant 
gender and race. The fifth question asked participants how long they had been 
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practicing pediatric gastroenterology. The last 3 questions gathered the following 
data on the practice: I) practice location; 2) practice setting; and 3) number of 
new patients with CD the practice sees in a year. 
Data Analysis 
To analyze the rankings, we used Study It software 33, which is a statistical 
package for running conjoint analysis. We first calculated the average ranking and 
average feasibility rating for each scenario. Then we determined the effect 
measurement of each change concept, and the effect measurement of the 
interaction between change concepts. 
L 
Results 
Participant Characteristics 
Of the 12 physicians that were contacted, 1 physician completed the 
survey for a response rate of 8.3%. The participant is a white male who has been 
practicing pediatric gastroenterology for 15 years. He currently works for an 
urban group practice that sees about 20 new patients with Crohn's disease every 
year. 
Conjoint Analysis Data 
The reported rankings and feasibility for each scenario are summarized in 
the 2 shaded colunms of Table 4. The participant ranked scenario D, which 
promoted family and patient self management, as the most likely to improve 
outcomes for patients with Crohn's disease. Scenario C, which implemented al15 
concept changes, was ranked as second. He ranked scenario M, which decreased 
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use and duration of steroids, and scenario N, which implemented planned care, as 
least likely to improve outcomes. The participant reported that no scenarios were 
very feasible (rating of 1 or 2). Scenarios Hand K-0 were all rated as being the 
least feasible. 
The effect of each change concept on ranking is summarized in Table 5. 
These results are also shown graphically in the dot diagram in Figure 6. The 
change concept most likely to improve outcomes is decreasing steroid use and 
duration (RX) because this concept has the largest effect size to the left of zero. 
On average, adding decreasing use and duration of steroids to a scenario increased 
ranking by 3 points. On the other hand, optimizing nutritional assessment and 
management (Nutr) and planned care (Plan) are the change concepts with the 
largest effect size to the right of zero. Adding one of those two concepts to a 
clinical scenario decreased its ranking by 4.25. Therefore, in the view of this 
respondent, these two change concepts are not likely to improve outcomes. 
The effect of interaction between two change concepts on ranking is 
shown in Figure 6. The pair of concepts that is furthest away from zero, and 
therefore has the largest effect size, is standardized diagnostic evaluation and 
planned care. This interaction is shown in Figure 7 by the two intersecting lines. 
The response plot shows that the effect of standardized diagnostic evaluation is 
dependent on planned care and vice versa. Therefore, adding standardized 
diagnostic evaluation to a scenario decreases ranking by 5.75 points if planned 
care is absent but only by 0.25 if planned care is present. Similarly, adding 
planned care to a scenario decreases ranking by 7.25 points if standardized 
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diagnostic evaluation is absent but only by 1.25 if standardized diagnostic 
evaluation is present. 
Discussion 
The goal of this study was to determine if conjoint analysis can be used to 
summarize current beliefs among pediatric gastroenterologists regarding the best 
way to change current CD management. Our results suggest that, according to one 
expert in the field, the change concept most likely to improve outcomes in 
pediatric CD patients is decreasing use and duration of steroids while the change 
concepts least likely to improve outcomes are planned care and optimizing 
nutritional assessment and management. The conjoint analysis shows that 
standardized diagnostic evaluation and planned care have the largest interaction 
effect. 
Although no studies have used conjoint analysis to determine which 
attributes of disease management physicians believe are most important, many 
studies have used conjoint analysis to determine patient preferences for 
treatment.21 ' 23 ' 34 For example, using conjoint analysis, Johansson et al. 
determined that most asthma patients prefer using a combination inhaler for both 
acute asthma attacks and maintenance therapy.21 They also concluded that 
patients were willing to pay more for their preferred medications. Only one study, 
by Brown, Swinyard, and Ogle, used conjoint analysis to determine physician 
preferences.Z2 However, rather than surveying physicians on treatment 
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preferences for their patients, they surveyed physicians on the value of different 
attributes regarding potential job offers. 
The conjoint method used in this analysis was a traditional full profile 
conjoint analysis. Stanek eta!. used this method to study individual preferences 
for congestive heart failure treatment outcomes?4 Each study participant was 
given 16 different health state scenarios and were asked to rate them from 0 (least 
desirable) to 10 (most desirable). Each scenario was written as bulleted points 
rather than paragraph form. In this study, we chose not to write our scenarios as 
bulleted points because we were worried that participants would dissect each 
scenario as they ranked them rather than looking at the scenario as a whole. This 
could lead to an analysis with no interaction effects. On the other hand, the 
paragraph form may be so overwhelming for participants that they can no longer 
differentiate between them, making the results unreliable. 
Based on our literature review7 and reviews on steroid use for CD,4•28 
consensus exists in the literature about the importance of decreasing use and 
duration of steroids. Aminosalicylates are considered first-line treatment, but for 
patients who are steroid dependent, the thiopurine agents should be used to reduce 
steroid use? This consensus in the literature supports our result of decreasing 
steroid use as the change concept most likely to improve outcomes. 
Guidelines for optimizing nutrition from our literature review clearly state 
the importance of nutrition screening for all children with IBD and the use of 
enteral or parenteral nutrition for children with growth retardation. 27 Therefore, 
our result of optimizing nutritional assessment and management as a change 
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concept that is unlikely to improve outcomes is unexpected. This may be because 
the respondent felt that optimizing nutrition was not feasible and therefore would 
be ineffective. On the other hand, his past experiences may have shown him that 
optimizing nutrition does not improve outcomes. 
Finally, our results also suggest that, in the view of one gastroenterologist, 
introducing planned care to CD management would not be likely to improve 
outcomes. Since the literature regarding this change concept is limited, this belief 
maybe based on the physician's own experiences with planned care. Planned care 
requires the interaction of professionals from different disciplines, which may 
affect feasibility. Therefore, our participant may have felt that planned care at 
most CD clinics would be minimal and play a small role in improving outcomes. 
It is difficult to know if conjoint analysis can accurately summarize 
current beliefs among pediatric gastroenterologists for CD management because 
only one physician responded to our survey. The limited sample also makes it 
difficult to draw any conclusions from the results, because our study sample may 
not be representative of all the PIBD network members. To strengthen our results, 
we will need to increase our sample size by administering the survey to more 
PIBD network members. To improve our response rate, we may have to provide 
physicians an incentive because the survey can take an hour of their time. Or, 
rather than administer the survey online, it may be easier to administer in person 
because we could place each scenario on an index card and ask participants to 
rank the cards. With these potential changes in mind, we plan to administer this 
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survey to all of the PIBD Network members who will be participating in the 
improvement collaborative that will begin in the fall of2006. 
Conclusion 
Variation in diagnostic evaluation and treatment therapies for pediatric CD 
exists and our systematic literature review shows limited consensus on the best 
way to manage pediatric CD. Therefore, we must rely on data gathered from 
experts in pediatric gastroenterology to identify the best way to manage CD. 
Conjoint analysis, a tool used in quality improvement, has been used to 
measure patient preferences for treatment, but our results suggest it can be used to 
summarize current beliefs among physicians. However, the low response rate of 
this study requires repeating this study with a larger sample before it can be used 
reliably. 
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Figure 1. Flow Diagram of Systematic Review 
Searching Ovid, Pubmed, 
and Clearinghouse 
guidelines, found 73 
potential articles 
Searching references of 
relevant articles and 
talking to experts, found 4 
relevant articles 
• 9 articles assessed 
as relevant 
t ~ 
7 abstracts were 
relevant to 
guidelines for 
pediatric IBD 
~ ~ 
4 articles met 
inclusion criteria 
• 
Total of 5 articles 
were accepted and 
critically appraised 
2 abstracts did 
not meet outcome 
criteria 
3 articles did not 
meet outcome 
criteria 
2 abstracts and 1 
article did not 
meet outcome 
criteria 
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Inclusion Criteria 
•Published in English 
•Published before March 2006 
•Outcome included guidelines 
or recommendations for 
pediatric CD 
~-~A- ~· E . A-- -- G - --- Seal - --
Grade Score 
Poor <8 
Fair 8- 14 
Good > 14 
Table 2. Evidence Table25 
Guideline 
Format& 
Development 
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Table 2.Cont. 
Identification & 
Summary of 
Evidence 
Method of identifying scientific 
evidence specified 
Formulation of I Role of value judgments used 
Recommendations by guideline developers in 
making recommendations is 
discussed 
ESPGHAN 
no 
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Escher et al Sands et al. Scott et al ASPEN 
no no 
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Table 2.Cont. 
Total Score* 
Grade 
*Maximum score of 25 
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Table 3. Descriptions of Change Concepts in Clinical Scenarios 
Chan~:e Implemented Change Not Implemented 
Standardize You use a standardized diagnostic evaluation to stratify You develop a diagnostic evaluation 
Diagnostic patients by disease severity and type. plan for new patients according to the 
Evaluation patient's presentation. 
Optimize You assess nutritional status at every visit and classify For most of your patients, you 
Nutritional the patients' nutritional status as at risk, in nutritional identify, evaluate and manage 
Assessment and failure, or acceptable and then treat accordingly. nutritional or growth failure. 
Management 
Planned care Each of your patients is assigned a care team which You review the patient's medical 
meets each week to review goals and plan interventions record at each visit. 
for the patients scheduled during the upcoming week. 
Promote Patient & You promote patient and family self management by You continue to educate patients and 
Family Self- meeting with the patients, their families, and other care their families as you do now. 
Management providers to set goals in areas such as school attendance 
and disease management and then develop interventions 
to reach each goal. 
Decrease Use and Patients that you classify as having moderate to severe You provide patients individualized 
Duration of Steroids disease enter an evidence-based protocol to reduce treatment based on your analysis of 
steroid use through the safe and effective use of their disease severity. 
mercaptopurine and other steroid sparing agents. 
L ........ 
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Table 4. Matrix Form of 16 Scenanos (non-shaded) and Participant Results 
Decrease Optimize 
Standardize use& nutritional I Promote family 
diagnostic duration of assessment & Planned & patient self 
Scenario evaluation steroids management care 
A + + I + 
B + + 
c + + 
-
D 
-
E + + + 
F + + I + 
G + + l I + 
H + 
I + + I + 
J + + l + 
K + + + 
L + + + 
M + 
N + 
0 + 
p + I + I + 
*Ranking is on a scale of I to 16 where I is most likely to improve outcomes and 16 is least likely to improve outcomes. 
A feasibility is on a scale of 1-5 where I is most feasible and 5 is least feasible. 
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Figure 2. Dot Diagram Results: First Pilot Study (n=l7) 
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Effect Size 
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management, Plan= Planned Care, DX =Standardize diagnostic evaluation, x =interaction (such that DXxNutr refers to the interaction of 
Standardize diagnostic evaluation and Optimize Nutritional Assessment and Management, etc.) 
6.15 
Figure 3. Response Plot for Effect of Self and RX 
Interaction: First Pilot Study* (n=17) 
16 
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' 
' 
' 
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' 
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*Self= Promote patient & family self-management, RX = 
Decrease use and duration of steroids, ( +) means the change 
concept is implemented while (-) means the it is not implemented 
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Figure 4. Dot Diagram Results: Second Pilot Study (n=2) 
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4 
RX ~Decrease use and duration of steroids, Nutr ~ Optimize Nutritional Assessment and Management, Self= Promote patient & family self-
management, Plan~ Planned Care, DX ~Standardize diagnostic evaluation, x ~interaction (such that DXxNutr refers to the interaction of Standardize 
diagnostic evaluation and Optimize Nutritional Assessment and Management, etc.) 
·······n11~··-rT1rlrr··· 
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Figure 5. Response Plot for Effect of Self and RX Interaction: 
16 
8 
Second Pilot Study* (n=2) 
13.63 
7.38 
·--
Self-
Self+ 
7.13 
-.. 
5.88 
0-+--r------------------+-------
RX + 
*Self~ Promote patient & family self-management, RX ~Decrease use and 
duration of steroids, ( +) means the change concept is implemented while (-) 
means the it is not implemented 
Table 5. Effect of Change Concept on Ranking (n= 1 )* 
Change Concept Effect on Ranking 
Standardize Diagnostic Evaluation 2.75 
Optimize Nutritional Assessment and 
Management 4.25 
Planned Care 4.25 
Promote Patient & Family Self-Management 
-0.25 
Decrease Use and Duration of Steroids 
-3.00 
*A negative effect means that ranking is increased and a positive effect means that 
ranking is decreased. A higher ranking is more likely to improve outcomes and a 
lower ranking is less likely to improve outcomes. 
Figure 6. Dot Diagram Results (n=l) 
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4.25 
RX =Decrease use aud duration of steroids, Nutr = Optimize Nutritional Assessment and Management, Self= Promote patient & family self-
management, Plan= Planned Care, DX =Standardize diagnostic evaluation, x =interaction (such that DXxNutr refers to the interaction of Standardize 
diagnostic evaluation and Optimize Nutritional Assessment and Management, etc.) 
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Figure 7. Response Plot for Effect of Plan and DX 
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*DX ~ Standardize diagnostic evaluation, Plan~ Planned 
Care, ( +) means the change concept is implemented 
while (-) means the it is not implemented 
Shilpa McManus 45 
Appendix A. Steps for Phase 0 of the Idealized Design Process16 
Step I: Select a topic 
Step 2: Obtain funding 
Step 3: Select a team 
Step 4: Develop a charter- describe goals by answering the following 3 
. 11 questions 
• What are we trying to accomplish? 
• How will we know that a change is an improvement? 
• What changes can we make that will result in improvement? 
Step 5: Capture what you know -review failures in current system and conduct a 
literature review 
Step 6: Select a high quality organization- select a clinic with good outcomes for 
their patients 
Step 7: Observe the clinic- determine the setting, how patients are behaving, 
interview groups, review available documents 
Step 8: Synthesize- brainstorm ideas using diagrams, mind mapping, post-its 
Step 9*: Screen- determine if ideas are desirable, different, feasible, and better 
than current practice; use conjoint analysis to narrow down the ideas 
Step 10: Expert meeting - experts review ideas and provide new insights 
*we chose to make the expert meeting part of step 9 and the conjoint analysis as part of step I 0 
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Appendix B. Definitions of Change Concepts 
Standardize Diagnostic Evaluation. Standardize diagnostic evaluation and 
stratify patients by disease severity and type. Disease severity is determined by 
evaluating signs and symptoms using a structured assessment tool (e.g., a 
checklist). 1 Disease type is determined using radiographic, endoscopic, and 
pathologic findings and specific staging criteria (e.g., Vienna criteria). 
Optimize Nutritional Assessment and Management. Stratify and manage 
patients according to their risk for nutritional or growth failure using BMI 
percentiles and height for age percentile. Patients with height z-scores less than 1 
below the mid-parental height z-score or patients in the 1 01h -25th BMI percentile 
are categorized as "at risk" and are evaluated for nutritional failure. Patients with 
height z-scores less than 2 below the mid-parental height z-score or patients in the 
<1 01h BMI percentile are categorized as having nutritional failure and are 
evaluated and treated. 
Planned Care. A care team (e.g., nurse coordinator or advanced practice nurse, 
dietician, and MD) is assigned to each patient and meets each week to review 
patients scheduled for the upcoming week. The review encompasses 
determination of disease activity, assessment of nutritional status, assessment of 
functional activity, and a review of the medication list. After identifying areas to 
focus on, interventions are planned to address each focus area. 
1 Diagnostic studies include complete blood count, serum albumin, ESR, C-reactive protein, liver profile, and 
stool collection for pathogens. 
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Promote Patient & Family Self-Management. To promote patient and family 
self management, patients, their families, and care providers set goals in areas 
such as school attendance, extracurricular activities, disease control, emergency 
action plan, medical management, and adherence to medical management and 
then develop interventions to reach each goal. Health care providers also use 
educational tools to teach patients how to care for their own disease. 
Decrease Use and Duration of Steroids. Patients classified as having moderate 
to severe disease enter an evidence-based protocol to reduce steroid use through 
the safe and effective use of mercaptopurine or other steroid sparing agents. For 
example, patients who start treatment with mercaptopurine are treated, monitored 
and assessed in a standard fashion. Deviations from the protocol are identified and 
the reason for each deviation recorded. 
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Appendix C. Paragraph Form of 16 Clinic Scenarios 
Scenario A 
You use a standardized diagnostic evaluation to stratify patients by disease 
severity and type. Patients that you classify as having moderate to severe disease 
enter an evidence-based protocol to reduce steroid use through the safe and 
effective use of mercaptopurine and other steroid sparing agents. You review the 
patient's medical record at each visit For most of your patients, you identify, 
evaluate and manage nutritional or growth failure. You promote patient and 
family self management by meeting with the patients, their families, and other 
care providers to set goals in areas such as school attendance and disease 
management and then develop interventions to reach each goaL 
Scenario B 
Each of your patients is assigned a care team which meets each week to review 
goals and plan interventions for the patients scheduled during the upcoming week. 
You develop a diagnostic evaluation plan for new patients according to the 
patient's presentation. You provide patients individualized treatment based on 
your analysis of their disease severity. You assess nutritional status at every visit 
and classify the patients' nutritional status as at risk, in nutritional failure, or 
acceptable and then treat accordingly. You promote patient and family self 
management by meeting with the patients, their families, and other care providers 
to set goals in areas such as school attendance and disease management and then 
develop interventions to reach each goaL 
Scenario C 
You use a standardized diagnostic evaluation to stratify patients by disease 
severity and type. Patients that you classify as having moderate to severe disease 
enter an evidence-based protocol to reduce steroid use through the safe and 
effective use of mercaptopurine and other steroid sparing agents. You assess 
nutritional status at every visit and classify the patients' nutritional status as at 
risk, in nutritional failure, or acceptable and then treat accordingly. Each of your 
patients is assigned a care team which meets each week to review goals and plan 
interventions for the patients scheduled during the upcoming week. You promote 
patient and family self management by meeting with the patients, their families, 
and other care providers to set goals in areas such as school attendance and 
disease management and then develop interventions to reach each goaL 
Scenario D 
You develop a diagnostic evaluation plan for new patients according to the 
patient's presentation. For most of your patients, you identify, evaluate and 
manage nutritional or growth failure. You provide patients individualized 
treatment based on your analysis of their disease severity. You review the 
patient's medical record at each visit. You promote patient and family self 
management by meeting with the patients, their families, and other care providers 
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to set goals in areas such as school attendance and disease management and then 
develop interventions to reach each goaL 
Scenario E 
You review the patient's medical record at each visit. You use a standardized 
diagnostic evaluation to stratify patients by disease severity and type. Patients that 
you classify as having moderate to severe disease enter an evidence-based 
protocol to reduce steroid use through the safe and effective use of 
mercaptopurine and other steroid sparing agents. You assess nutritional status at 
every visit and classify the patients' nutritional status as at risk, in nutritional 
failure, or acceptable and then treat accordingly. You continue to educate patients 
and their families as you do now. 
Scenario F 
Each of your patients is assigned a care team which meets each week to review 
goals and plan interventions for the patients scheduled during the upcoming week. 
You continue to educate patients and their families as you do now. You develop a 
diagnostic evaluation plan for new patients according to the patient's presentation. 
Patients that you classify as having moderate to severe disease enter an evidence-
based protocol to reduce steroid use through the safe and effective use of 
mercaptopurine and other steroid sparing agents. You assess nutritional status at 
every visit and classify the patients' nutritional status as at risk, in nutritional 
failure, or acceptable and then treat accordingly. 
Scenario G 
You review the patient's medical record at each visit. You use a standardized 
diagnostic evaluation to stratify patients by disease severity and type. You provide 
patients individualized treatment based on your analysis of their disease severity. 
You promote patient and family self management by meeting with the patients, 
their families, and other care providers to set goals in areas such as school 
attendance and disease management and then develop interventions to reach each 
goaL You assess nutritional status at every visit and classify the patients' 
nutritional status as at risk, in nutritional failure, or acceptable and then treat 
accordingly. 
Scenario H 
You provide patients individualized treatment based on your analysis of their 
disease severity. For most of your patients, you identify, evaluate and manage 
nutritional or growth failure. You review the patient's medical record at each visit. 
You continue to educate patients and their families as you do now. You use a 
standardized diagnostic evaluation to stratify patients by disease severity and type. 
Scenario I 
You promote patient and family self management by meeting with the patients, 
their families, and other care providers to set goals in areas such as school 
attendance and disease management and then develop interventions to reach each 
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goal. Each of your patients is assigned a care team which meets each week to 
review goals and plan interventions for the patients scheduled during the 
upcoming week. You use a standardized diagnostic evaluation to stratify patients 
by disease severity and type. For most of your patients, you identify, evaluate and 
manage nutritional or growth failure. You provide patients individualized 
treatment based on your analysis of their disease severity. 
Scenario J 
You review the patient's medical record at each visit. You assess nutritional status 
at every visit and classify the patients' nutritional status as at risk, in nutritional 
failure, or acceptable and then treat accordingly. You develop a diagnostic 
evaluation plan for new patients according to the patient's presentation. Patients 
that you classify as having moderate to severe disease enter an evidence-based 
protocol to reduce steroid use through the safe and effective use of 
mercaptopurine and other steroid sparing agents. You promote patient and family 
self management by meeting with the patients, their families, and other care 
providers to set goals in areas such as school attendance and disease management 
and then develop interventions to reach each goal. 
Scenario K 
You continue to educate patients and their families as you do now. Each of your 
patients is assigned a care team which meets each week to review goals and plan 
interventions for the patients scheduled during the upcoming week. You use a 
standardized diagnostic evaluation to stratify patients by disease severity and type. 
Patients that you classify as having moderate to severe disease enter an evidence-
based protocol to reduce steroid use through the safe and effective use of 
mercaptopurine and other steroid sparing agents. For most of your patients, you 
identify, evaluate and manage nutritional or growth failure. 
Scenario L 
You use a standardized diagnostic evaluation to stratify patients by disease 
severity and type. You provide patients individualized treatment based on your 
analysis of their disease severity. You continue to educate patients and their 
families as you do now. Each of your patients is assigned a care team which meets 
each week to review goals and plan interventions for the patients scheduled 
during the upcoming week. You assess nutritional status at every visit and classify 
the patients' nutritional status as at risk, in nutritional failure, or acceptable and 
then treat accordingly. 
Scenario M 
You develop a diagnostic evaluation plan for new patients according to the 
patient's presentation. You review the patient's medical record at each visit. For 
most of your patients, you identify, evaluate and manage nutritional or growth 
failure. Patients that you classify as having moderate to severe disease enter an 
evidence-based protocol to reduce steroid use through the safe and effective use 
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of mercaptopurine and other steroid sparing agents. You continue to educate 
patients and their families as you do now. 
Scenario N 
You develop a diagnostic evaluation plan for new patients according to the 
patient's presentation. Each of your patients is assigned a care team which meets 
each week to review goals and plan interventions for the patients scheduled 
during the upcoming week. For most of your patients, you identify, evaluate and 
manage nutritional or growth failure. You provide patients individualized 
treatment based on your analysis of their disease severity. You continue to 
educate patients and their families as you do now. 
Scenario 0 
You review the patient's medical record at each visit. You continue to educate 
patients and their families as you do now. You develop a diagnostic evaluation 
plan for new patients according to the patient's presentation. You assess 
nutritional status at every visit and classify the patients' nutritional status as at 
risk, in nutritional failure, or acceptable and then treat accordingly. You provide 
patients individualized treatment based on your analysis of their disease severity. 
Scenario P 
You promote patient and family self management by meeting with the patients, 
their families, and other care providers to set goals in areas such as school 
attendance and disease management and then develop interventions to reach each 
goal. You develop a diagnostic evaluation plan for new patients according to the 
patient's presentation. Patients that you classify as having moderate to severe 
disease enter an evidence-based protocol to reduce steroid use through the safe 
and effective use of mercaptopurine and other steroid sparing agents. For most of 
your patients, you identify, evaluate and manage nutritional or growth failure. 
Each of your patients is assigned a care team which meets each week to review 
goals and plan interventions for the patients scheduled during the upcoming week. 
Shilpa McManus 52 
References 
1. Kugathasan S, Judd RH, Hoffmann RG, eta!. Epidemiologic and clinical 
characteristics of children with newly diagnosed inflammatory bowel disease in 
Wisconsin: A statewide population-based study. J Pediatr. 2003;143:525-531. 
2. Bentley D, Lifschitz C, Lawson M. Inflammatory bowel disease. In: Pediatric 
Gastroenterology and Clinical Nutrition. London, UK: ReMedica Publishing; 
2001:1-26. 
3. IBD Working Group of the European Society for Paediatric Gastroenterology, 
Hepatology and Nutrition. Inflammatory bowel disease in children and 
adolescents: Recommendations for diagnosis--the Porto Criteria. J Pediatr 
Gastroenterol Nutr. 2005;41:1-7. 
4. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429. 
5. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for 
patients with chronic illness. JAMA. 2002;288:1775-1779. 
6. Colletti R, Baldassano R, Milov D, Margolis P. PIBDNet-the pediatric IBD 
network for research and improvement. Variation in initial evaluation and 
treatment of pediatric Crohn disease. Poster presentation at the North American 
Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual 
Meeting. Salt Lake City: October 2005. 
7. Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ. Treatment of 
inflammatory bowel disease in childhood: Best available evidence. Injlamm 
Bowel Dis. 2003;9:34-58. 
8. Chassin MR. Practice guidelines: Best hope for quality improvement in the 
1990s. J Occup Med. 1990;32:1199-1206. 
9. Berwick DM. A primer on leading the improvement of systems. BMJ. 
1996;312:619-622. 
10. Deming W. The New Economics: For Industry, Government, and Education. 
Massachusetts: MIT, CAES; 1993. 
11. Langley G, Nolan K, Nolan T, Norman C, Provost L. The Improvement 
Guide: A Practical Approach to Enhancing Organizational Peiformance. San 
Francisco, CA: J ossey-Bass; 1996. 
12. Schechter MS, Margolis P. Improving subspecialty healthcare: Lessons from 
cystic fibrosis. J Pediatr. 2005;147:295-301. 
Shilpa McManus 53 
13. Institute ofMedicine Committee on Quality Health Care in America. Crossing 
the Quality Chasm: A New Health System for the 21st Century. Washington, DC: 
National Academy Press; 2001. 
14. Chassin MR, Galvin RW. The urgent need to improve health care quality. 
institute of medicine national roundtable on health care quality. JAMA. 
1998;280: 1000-1005. 
15. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. 
Improving chronic illness care: Translating evidence into action. Health Aff 
(Millwood). 2001;20:64-78. 
16. Moen R. A Guide for Idealized Design. A Working Paper Prepared for the 
Institute for Healthcare Improvement. Institute for Healthcare Improvement; 2002. 
17. White B. Starting a revolution in office-based care. Fam Pract Manag. 
2001;8:29-35. 
18. Radel SJ, Norman AM, Notaro JC, Horrigan DR. Redesigning clinical office 
practices to improve performance levels in an individual practice association 
model HMO. J Healthc Qual. 2001;23:11-5; quiz 15, 52. 
19. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for 
patients with chronic illness: The chronic care model, part 2. JAMA. 
2002;288:1909-1914. 
20. Shepanski MA, Markowitz JE, Mamula P, Hurd LB, Baldassano RN. Is an 
abbreviated pediatric Crohn's disease activity index better than the original? J 
Pediatr Gastroenterol Nutr. 2004;39:68-72. 
21. Johansson G, Stallberg B, Tomling G, et al. Asthma treatment preference 
study: A conjoint analysis of preferred drug treatments. Chest. 2004;125:916-923. 
22. Brown AJ, Swinyard W, Ogle J. Women in academic medicine: A report of 
focus groups and questionnaires, with conjoint analysis. J Womens Health 
(Larchmt). 2003; 12:999-1008. 
23. Gan TJ, Lubarsky DA, Flood EM, et al. Patient preferences for acute pain 
treatment. Br J Anaesth. 2004;92:681-688. 
24. Orme B. Which conjoint method should I use? Sequim, WA: Sawtooth 
Software, Inc; 2003. Available from: 
http://www.sawtoothsoftware.com/download/techpap/whichmth.pdf. 
25. Shaneyfelt TM, Mayo-Smith MF, Rothwang1 J. Are guidelines following 
guidelines? The methodological quality of clinical practice guidelines in the peer-
reviewed medical literature. JAMA. 1999;281:1900-1905. 
Shilpa McManus 54 
26. American Society for Parenteral and Enteral Nutrition. Guidelines for the use 
of parenteral and enteral nutrition in adult and pediatric patients. JP EN. 
2002;26:1SA-1SA-6SA. 
27. American Society for Parenteral and Enteral Nutrition. Specific guidelines for 
disease-pediatrics. JPEN. 2002;26:111SA-111SA -138SA. 
28. Rampton DS. Management ofCrohn's disease. BMJ. 1999;319:1480-1485. 
29. Sands BE, Cuffari C, Katz J, et a!. Guidelines for immuuizations in patients 
with inflammatory bowel disease. Injlamm Bowel Dis. 2004;10:677-692. 
30. Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac 
disease and inflammatory bowel disease. British society of gastroenterology. Gut. 
2000;46 Suppll:il-8. 
31. Milov D, Baldassano R, Colletti R, Margolis P. PIBDNet-the pediatric IBD 
network for research and improvement. Poster presentation at the North 
American Society for Pediatric Gastroenterology, Hepatology and Nutrition 
Annual Meeting. Salt Lake City: October 2005. 
32. Moen R, Nolan T, Provost L. Quality Improvement through Planned 
Experimentation. 2nd ed. USA: McGraw Hill; 1999. 
33. Imboden J. Study-it. 1998. 
34. Stanek EJ, Oates MB, McGhan WF, Denofrio D, Loh E. Preferences for 
treatment outcomes in patients with heart failure: Symptoms versus survival. J 
Card Fail. 2000;6:225-232. 
